JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $40,205,000 | -0.2% | 879,560 | -2.1% | 0.07% | -6.7% |
| Q3 2017 | $40,286,000 | +49.5% | 898,040 | -0.4% | 0.08% | +44.2% |
| Q2 2017 | $26,953,000 | +31.4% | 901,750 | -2.5% | 0.05% | +26.8% |
| Q1 2017 | $20,518,000 | +14.8% | 924,650 | -2.5% | 0.04% | +10.8% |
| Q4 2016 | $17,876,000 | -41.7% | 948,320 | -7.1% | 0.04% | -42.2% |
| Q3 2016 | $30,640,000 | -16.9% | 1,021,000 | +6.4% | 0.06% | -21.0% |
| Q2 2016 | $36,873,000 | -2.4% | 959,230 | -3.3% | 0.08% | -4.7% |
| Q1 2016 | $37,773,000 | – | 991,680 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |